RxDoctor Payments Data

Andrew Ruppersberger, DO

Family Medicine · Levittown, PANPI 1164472486

Payments from drug & device makers

$15,915in general payments, 2019–2025

Across 1,079 payments — averaging $14.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$2K
  • Lilly USA, LLC$2K
  • Pfizer$1K
  • AstraZeneca$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$915
  • plus $6K from 54 others

What the payments were for

  • Food & beverage$15,889100%
  • Education$260%
  • Gifts$00%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)171$2,268
Novo Nordisk130$1,876
Lilly USA, LLC107$1,574
Pfizer144$1,490
AstraZeneca(2 entities)86$1,382
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC70$915
GSK36$536
Bayer26$494
Boehringer Ingelheim22$407
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)17$352
Amgen(2 entities)21$321
Scilex Pharmaceuticals Inc.20$314
Astellas Pharma US Inc17$307
Exact Sciences16$304
Axsome Therapeutics, Inc.15$276
Biohaven Pharmaceuticals, Inc.10$219
Lundbeck LLC11$197
Merck12$189
Teva Pharmaceuticals USA, Inc.14$188
Otsuka America Pharmaceutical, Inc.10$175
Biohaven Pharmaceutical Holding Company Ltd.9$142
Novartis9$138
Sanofi-aventis U.S. LLC7$116
Vanda Pharmaceuticals Inc.4$97
Johnson & Johnson5$86
Dexcom, Inc.5$85
Sumitomo Pharma America, Inc.4$84
Boston Scientific3$83
Verona Pharma, Inc.3$75
Arbor Pharmaceuticals, Inc.5$75
Eisai Inc.5$72
Abbott4$70
Tolmar, Inc.4$68
Amarin Pharma, Inc.5$66
Verity Pharmaceuticals Inc.4$61
Takeda Pharmaceuticals U.S.A., Inc.4$58
Idorsia Pharmaceuticals US Inc3$51
IBSA Pharma Inc.2$49
Corcept Therapeutics3$48
Aytu Biopharma, Inc.2$43
Xeris Pharmaceuticals, Inc.3$43
Inspire Medical Systems, Inc.2$38
Axonics, Inc.1$35
Sunovion Pharmaceuticals Inc.2$31
Optos, Inc.1$31
Collegium Pharmaceutical, Inc.2$31
Bausch Health US, LLC2$28
Alkermes, Inc.1$25
Otsuka Pharmaceutical Development & Commercialization, Inc.1$22
Tonix Medicines, Inc.1$21
Almatica Pharma LLC1$21
Vertos Medical, Inc.1$20
Jazz Pharmaceuticals Inc.1$20
Currax Pharmaceuticals LLC1$18
Genentech USA, Inc.1$16
Theracosbio, LLC1$16
Harmony Biosciences LLC1$14
Watermark Medical, Inc.1$14
E.r. Squibb & Sons, L.L.C.1$14
Bristol Myers Squibb1$14

How this compares

$15,915 in reported general payments places this provider in the 95th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$115,528
Medicare patients
375
Services billed
2,370

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban207$180,665
MounjaroTirzepatide112$121,619
OzempicSemaglutide89$104,342
TrulicityDulaglutide72$82,995
JardianceEmpagliflozin87$79,704
Trelegy ElliptaFluticasone/Umeclidin/Vilanter100$74,568
OxycontinOxycodone Hcl33$70,471
JanuviaSitagliptin Phosphate70$68,800
FarxigaDapagliflozin Propanediol54$49,475
VraylarCariprazine Hcl29$45,109
LinzessLinaclotide51$43,190
XareltoRivaroxaban29$31,120
Breo ElliptaFluticasone/Vilanterol64$29,145
EntrestoSacubitril/Valsartan28$28,768
XifaxanRifaximin12$24,703

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,574$204,614184 claims
PfizerEliquis, Abrysvo$1,490$194,869252 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Shingrix$536$130,796228 claims
AbbVieVraylar, Linzess, Ubrelvy, Synthroid$2,268$107,233169 claims
Novo NordiskOzempic$1,876$104,34289 claims
Boehringer IngelheimJardiance, Spiriva Respimat$407$94,058113 claims
AstraZenecaFarxiga, Breztri Aerosphere, Brilinta$1,382$75,83391 claims
MerckJanuvia$189$68,80070 claims
Johnson & JohnsonXarelto$86$31,12029 claims
NovartisEntresto$138$28,76828 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$915$24,70312 claims
Astellas Pharma US IncMyrbetriq$307$16,10632 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Levittown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →